Twist Bioscience Corporation Deferred Revenue Recognized
Twist Bioscience Corporation (TWST) reported Deferred Revenue Recognized of $2.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-03
- Twist Bioscience Corporation contract with customer, liability, revenue recognized for the quarter ending 2026-06-30 was $2.90M, a 70.59% increase year-over-year.
- Twist Bioscience Corporation contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $2.50M, a 316.67% increase year-over-year.
- Twist Bioscience Corporation contract with customer, liability, revenue recognized for the quarter ending 2025-12-31 was $2.30M, a 35.29% increase year-over-year.
- Twist Bioscience Corporation contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $1.70M, a 142.86% increase year-over-year.
- Twist Bioscience Corporation contract with customer, liability, revenue recognized for fiscal 2025 was $1.40M, a 17.65% decline from fiscal 2024.
- Twist Bioscience Corporation contract with customer, liability, revenue recognized for fiscal 2024 was $1.70M, a 39.29% decline from fiscal 2023.
- Twist Bioscience Corporation contract with customer, liability, revenue recognized for fiscal 2023 was $2.80M, a 154.55% increase from fiscal 2022.
- Twist Bioscience Corporation contract with customer, liability, revenue recognized for fiscal 2022 was $1.10M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.90M 10-Q · filed 2026-08-03 | $4.10M 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | $2.50M 10-Q · filed 2026-05-04 | $2.60M 10-Q · filed 2026-05-04 | ||
| 2025-12-31 | $2.30M 10-Q/A · filed 2026-02-26 | |||
| 2025-09-30 | $1.40M 10-K · filed 2025-11-17 | |||
| 2025-06-30 | $1.70M 10-Q · filed 2026-08-03 | $1.40M 10-Q · filed 2026-08-03 | ||
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-04 | $1.40M 10-Q · filed 2026-05-04 | ||
| 2024-12-31 | $1.70M 10-Q/A · filed 2026-02-26 | |||
| 2024-09-30 | $1.70M 10-K · filed 2025-11-17 | |||
| 2024-06-30 | $700.00K 10-Q · filed 2025-08-04 | $2.90M 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $900.00K 10-Q · filed 2025-05-05 | $2.20M 10-Q · filed 2025-05-05 | ||
| 2023-12-31 | $1.30M 10-Q · filed 2025-02-03 | |||
| 2023-09-30 | $2.80M 10-K · filed 2025-11-17 | |||
| 2023-06-30 | $600.00K 10-Q · filed 2024-08-02 | $2.80M 10-Q · filed 2024-08-02 | ||
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-02 | $2.70M 10-Q · filed 2024-05-02 | ||
| 2022-12-31 | $2.30M 10-Q · filed 2024-02-02 | |||
| 2022-09-30 | $1.10M 10-K · filed 2024-11-18 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 10-Q · filed 2021-05-07 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |